Review the side-effects of Polatuzumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist. 1.Blood: Anemia, low platelet count, low white blood cell count
2.Nervous system: Peripheral neuropathy, dizziness
3.Gastrointestinal system: Diarrhea, vomiting, decreased appetite, liver injury
4.General: Infusion-related pain, rash infections, fever, decreased weight, low potassium, low calcium
2.Premedicate patients with an antihistamine and antipyretic to reduce the chance of infusion-related reactions like rash and fever.
3.Monitor complete blood counts- RBC, WBC, Platelets.
4.Monitor for signs of bacterial or viral infections.
5.Monitor patients for new or worsening neurological, cognitive, or behavioral changes.
6.Monitor liver enzymes and bilirubin.
7.Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of Polatuzumab.
8.Advise patients not to breastfeed while taking Polatuzumab.
If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist. 1.Blood: Anemia, low platelet count, low white blood cell count
2.Nervous system: Peripheral neuropathy, dizziness
3.Gastrointestinal system: Diarrhea, vomiting, decreased appetite, liver injury
4.General: Infusion-related pain, rash infections, fever, decreased weight, low potassium, low calcium
Other Precautions :
1.Monitor patients for peripheral neuropathy (tingling of the hands or feet)2.Premedicate patients with an antihistamine and antipyretic to reduce the chance of infusion-related reactions like rash and fever.
3.Monitor complete blood counts- RBC, WBC, Platelets.
4.Monitor for signs of bacterial or viral infections.
5.Monitor patients for new or worsening neurological, cognitive, or behavioral changes.
6.Monitor liver enzymes and bilirubin.
7.Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of Polatuzumab.
8.Advise patients not to breastfeed while taking Polatuzumab.
